Denali Therapeutics (DNLI) Consolidated Net Income: 2017-2024
Historic Consolidated Net Income for Denali Therapeutics (DNLI) over the last 8 years, with Dec 2024 value amounting to -$114.7 million.
- Denali Therapeutics' Consolidated Net Income rose 4.01% to -$114.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$422.7 million, marking a year-over-year increase of 3.58%. This contributed to the annual value of -$422.8 million for FY2024, which is 191.12% down from last year.
- Denali Therapeutics' Consolidated Net Income amounted to -$114.7 million in Q4 2024, which was down 6.99% from -$107.2 million recorded in Q3 2024.
- In the past 5 years, Denali Therapeutics' Consolidated Net Income ranged from a high of $244.9 million in Q4 2020 and a low of -$119.5 million during Q4 2023.
- Over the past 3 years, Denali Therapeutics' median Consolidated Net Income value was -$102.6 million (recorded in 2022), while the average stood at -$99.6 million.
- As far as peak fluctuations go, Denali Therapeutics' Consolidated Net Income soared by 553.28% in 2020, and later plummeted by 130.73% in 2021.
- Over the past 5 years, Denali Therapeutics' Consolidated Net Income (Quarterly) stood at $244.9 million in 2020, then crashed by 130.73% to -$75.3 million in 2021, then slumped by 31.11% to -$98.7 million in 2022, then dropped by 21.07% to -$119.5 million in 2023, then grew by 4.01% to -$114.7 million in 2024.
- Its Consolidated Net Income was -$114.7 million in Q4 2024, compared to -$107.2 million in Q3 2024 and -$99.0 million in Q2 2024.